Press Releases July 31, 2026 08:00 AM

Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

Elutia Schedules Q2 2026 Financial Results Release and Conference Call on August 13

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
ELUT

Elutia Inc., a biotechnology company specializing in drug-eluting biomatrix technologies, announced it will release its second quarter 2026 financial results after market close on August 13, 2026. The company will host a conference call and webcast to discuss the earnings. Elutia focuses on improving compatibility between medical devices and patients, emphasizing advancements in implantable technologies.

Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
ELUT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Elutia to release Q2 2026 financial results on August 13, 2026, after market close.
  • Management will host a conference call and webcast to discuss the financial results.
  • The company specializes in drug-eluting biomatrix products aimed at enhancing medical device compatibility for implantable technologies.

GAITHERSBURG, Md., July 31, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2026 financial results after market close on Thursday, August 13, 2026. Members of the Company’s management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day.

The conference call can be accessed using the following information:

Webcast: Click here

Dial-In: Click here

To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the option to have the system dial-out to you once the conference call begins. If you forget your PIN prior to the conference call, you can simply re-register.

Please log in approximately 10 minutes prior to the scheduled start time. A live and archived webcast of the event will be available on the “Investors” section of the Elutia website at http://investors.elutia.com/.

About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Investors:
Elutia Investor Relations
[email protected]


Risks

  • Financial results could miss market expectations leading to investor disappointment.
  • The adoption rate of Elutia’s drug-eluting biomatrix technology in the medical device sector may be slower than anticipated.
  • Regulatory challenges related to medical device compatibility and implantation could affect product commercialization.

More from Press Releases

CN Releases 2026–2027 Grain Plan: Strengthening Canada’s Supply Chain Jul 31, 2026 SEALSQ Launches Commercial Phase of Miraex Quantum Photonics Technology Following Strategic Acquisition Jul 31, 2026 QTREX Proprietary Quantum Interconnect Platform Exceeds Performance Requirements Established by Strategic Partners Jul 31, 2026 Hesai Group to Hold 2026 Second Extraordinary General Meeting on August 28, 2026 Jul 31, 2026 NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing Jul 31, 2026